non-surgical. 7 The rate of post-surgical cases is similar across studies from 22 to 29 per 100 000 7, 8, 10 although lower in Norway at 10 per 100 000. 11 The rate of non-surgical cases was more variable from 2.3 (9) to 8 (8) to 17 (7) per 100 000. Our methodology, however, is likely to be more sensitive at identifying patients with milder hypoparathyroidism who may be missed using methods depending on hospital referral and patient registries.
Morbidities associated with hypoparathyroidism are either related directly to low calcium or raised phosphate concentrations or indirectly via treatment for the disorder which comprise oral calcium and vitamin D analogue supplements. 4, 12 In addition, some of the non-surgical cases are likely to be due to genetic mutations, for example, DiGeorge syndrome, which are known to be associated with congenital heart defects and urogenital abnormalities. 13 Other autoimmune aetiologies, for example, autoimmune polyglandular syndrome, are associated with Addison's disease and thyroid disease potentially placing patients at risk. 14, 15 Conventionally, the aim of treatment has been to maintain the serum calcium concentration around the lower limit of the reference range. This limits the risks of hypercalciuria and hypercalcaemia with the resultant risks of symptoms, renal stones and other complications. Previous studies have reported association between renal complications and hypoparathyroidism. 10, 16 The Danish national studies reported that patients with hypoparathyroidism had an increased risk of seizure, depression, neuropsychiatric diseases and infections, whereas there was no increased risk of cardiovascular disease, cataract, fracture or death. 10, 17 The aim of this study was to investigate whether patients with chronic hypoparathyroidism had an increased risk of incident cataract, cardiovascular disease, cerebrovascular disease, infections of skin and chest, epilepsy, fracture, mental health, renal failure and death.
| MATERIAL S AND ME THODS

| Patients and controls
All Tayside residents registered with a general practice in Scotland are assigned to a unique 10-digit health index, known as a
Community Health Index (CHI). CHI is used as a patient identifier
that facilitates the linkage of all health care-related records. All such records are held and linked at the Health Informatics Centre (https:// www.dundee.ac.uk/hic) of the University of Dundee. We have previously identified adult patients (age 18 years and over) between January 1988 and August 2016 with hypoparathyroidism using four principle anonymous patient-level datasets, and the patient selection and classification process is described in detail in Vadiveloo et al. 7 In brief, patients were identified from the Tayside population based on at least three outpatient-based measurements of serum albumin-corrected calcium below the reference range (≤2.15 mmol/L) with a minimum of a 1-month interval between measurements. All calcium measurements taken as an inpatient were excluded, 94%
of patients had a serum calcium below 2.10 mmol/L and 83% of patients had low serum calcium at least 6 months apart. In addition, concentrations, all within 1 month; (e) patients who had either serum creatinine>200 µmol/L or eGFR <20 prior to the first recording of a low serum calcium. Using an electronic-based algorithm to identify patients across the community is different to previous approaches, but arguably identifies patients missed when depending on referrals to a specialist and registration on specific databases, especially nonsurgical cases. These issues have been discussed elsewhere. 7 Our patients were subcategorized as having post-surgical hypoparathyroidism, or having non-surgical hypoparathyroidism 7 or having hypoparathyroidism associated with hypomagnesaemia (<0.5 mmol/L:
lower limit of local reference range is 0.69 mmol/L). This last group
was assessed separately as some of these patients will have had hypomagnesaemia due to hypoparathyroidism, but some will have had hypomagnesaemia causing the hypocalcaemia, and may not truly have hypoparathyroidism. Drugs which can cause hypomagnesaemia and lower serum calcium include diuretics and proton pump inhibitors, which are markers of confounding comorbidities such as heart failure and may have influence the outcomes.
In this study, a group of controls from the general Tayside population who had serum calcium concentration within the laboratory reference range were identified and were matched to cases with hypoparathyroidism. For each patient with hypoparathyroidism, five controls were randomly selected, matched by gender, age (± 5 years) and diabetes status. Each comparator was assigned an index date (start of follow-up) identical to the date of diagnosis for hypoparathyroidism of the case. Date of diagnosis was defined as the first low calcium measurement.
| Databases and data validity
| Tayside population demographic database
This served as a master index to provide information on gender, date of birth, date of death and dates registered with general practitioner.
This information was obtained from the National CHI register and contained 99% of the population. This was validated by the external systems before it reached the Health Informatics Centre.
| Scottish morbidity record 1
The Scottish morbidity record 1 (SMR01) dataset was used to obtain information on morbidity. This dataset consisted of hospital 
| Tayside prescription database
This contained all prescriptions dispensed from all community pharmacies in Tayside. Each entry comprised the patient's anonymized CHI, prescription date, drug name, formulation, dosage, frequency and duration. These data were received from
Practitioner Services Divisions, and we were given access to all prescriptions for anti-epileptic, anti-depressant and anti-psychotic medications.
| Biochemistry database
The biochemistry database contained information on serum calcium, parathyroid hormone concentrations and vitamin D concentrations which were used to define the cohort as described previously. 7 eGFR measurements were also available to define renal failure. Each entry comprised the patient's anonymized CHI, the test performed, date and the results. These data were received directly from the laboratory systems and were validated routinely.
| Statistical methods
The following outcomes of all patients with hypoparathyroidism were identified: cataract, cardiovascular disease, cerebrovascular disease, infections of skin and chest (eg, cellulitis and pneumonia), epilepsy, fracture, mental health, renal failure and death. SMR01, the admission database was used to identify all the above outcomes. Patients who had epilepsy and mental health problem were also identified using the prescribing database. Patients who had renal failure were identified using the eGFR measurements in the biochemistry database. Renal failure was defined as eGFR below 30 mL/min. Survival analysis was used to follow up patients until an event occurred, they were censored or the end of the study. Cox proportional hazards model was used to model the data, and the assumption of proportional hazards was assessed using the graphical with five matched controls (age and gender) from the Tayside population. The association between mean calcium concentration after diagnosis and all the outcomes was also investigated. All analyses were performed on anonymized datasets using IBM spss Statistics 22
(Armonk, NY, USA) and sas 9.4.
| Other confounders
Apart from gender and age, other covariates adjusted for in the survival analysis were socioeconomic deprivation and previous history of the disease studied.
| Ethical approval
The study was approved by the Tayside Medical Ethics Committee and data protection by the Tayside Caldicott Guardians.
| RE SULTS
There were a total of 280 patients with chronic hypoparathyroidism, of which 116 cases were post-surgical, 58 cases had hypomagnesaemia and 106 cases were non-surgical. 7 The total follow-up period was 2587 years with a median of 9 years. Overall, 30.7% of the cases were male, and the mean age was 51.6 years (SD 19). The baseline characteristics of hypoparathyroid cases and reference population are shown in Table 1 . At baseline, significantly higher percentages of hypoparathyroid cases had pre-existing infections (P < 0.001), cardiovascular disease (P = 0.001), fractures (P = 0.004), mental health conditions (P < 0.001) and renal failure (P < 0.001) compared to the reference population.
There was no violation of the assumption of proportional hazards in all outcomes except for renal failure. A proportional hazards model was used to assess all outcomes except for renal failure when a non proportional hazard model was used. Table 2 shows the unadjusted and adjusted hazard ratios (HR) for inpatient admissions due to cataract, cardiovascular disease, cerebrovascular disease, infection, epilepsy, fracture, mental health and death. The total number of events for each disease studied was cardiovascular disease excluded, which is a marker of chronic ill health, the adjusted mortality rate remained significant with a hazards ratio of 1.44 (1.02-2.02; P = 0.037). There were no significant differences in the risk of fracture between hypoparathyroid patients and the matched reference population. When the hypoparathyroid patients were grouped into two categories, patients in the post-surgical group had a significantly increased risk of cataract and epilepsy compared with the reference population.
However, those in non-surgical group had increased risk of cardiovascular disease, cerebrovascular disease, epilepsy, infection, mental health and death compared with the reference population.
Those with hypomagnesaemia-associated hypoparathyroidism had increased risk of cardiovascular disease, cataracts, infection, fractures mental health and death. This risk profile is similar, but not identical to those with non-surgical hypoparathyroidism, but the hazards ratios seem to be greater for the hypomagnesaemia group.
The cumulative martingale residuals plots showed that the proportional hazard assumption was violated for all cases and non-surgical cases whereby the true hazard ratio for renal failure was changing over time. The hazard ratio was found changing at 2000 days after baseline for the non-surgical group; therefore, the follow-up time from baseline was split for the overall group and this subgroup: ≤2000 and>2000 days. Table 3 shows the unadjusted and Table 4 shows that serum calcium concentration was positively associated with renal failure and death, but otherwise mean serum calcium was not associated with any of the outcomes.
| D ISCUSS I ON
In this study, we demonstrated an increased death rate with in- those observed from Denmark, where there was an increased risk of all the same outcomes with no risk of fractures in non-surgical hypoparathyroidism. 9 The Danish study showed a borderline increased risk mortality in non-surgical hypoparathyroidism which did not quite reach statistical significance (HR 1.25, P = 0.06) 9 but no increased mortality for post-surgical cases. 10 In addition
TA B L E 2 Hazard ratios for inpatient admissions and death for hypoparathyroid patients
to an increased risk of renal failure and seizures for patients with post-surgical hypoparathyroidism, the Danish study also showed a risk for mental illness and infection, 10, 17 although they did not demonstrate any risk for cataracts unlike our study. They had a greater number of patients and may have been better powered to demonstrate these end-points which showed a non-significant trend in our study.
Our Scottish cohort and the Danish cohort are the only two reported population-based case-controlled follow-up studies in hypoparathyroidism that we are aware of. It is an important finding that our data confirmed the previous findings, but also showed a twofold increased death rate in patients with non-surgical hypoparathyroidism, a finding which did not quite reach significance in the previous study. In addition, our study was able to provide a simultaneous comparison between post-surgical and non-surgical cases and hypomagnesaemia cases. It is likely that the vast majority of the group with hypomagnesaemia are non-surgical cases, and they demonstrated greatest risk for death and most (but not all)
outcomes measured, although they may be confounded by coexisting comorbidities. There was also a greater risk for people with non-surgical hypoparathyroidism (normal magnesium concentrations) compared to those with post-surgical hypoparathyroidism.
As post-surgical cases occur acutely and not insidiously, they are more likely to be recognized early and referred to a specialist clinic where they may get better long-term care. Non-surgical cases may be linked with other coexisting conditions such as Addison's disease and other autoimmune disease or genetic disorders which may add to their risk. We should be encouraging all cases of persistent hypocalcaemia to be referred to a specialist clinic so that all these issues can be addressed.
Others have shown increased morbidity with high rates of renal failure, renal and basal ganglia calcification, 16 along with poor quality of life and heightened anxiety scores, 11 mental illness 19 and reduced employability. 20 These outcomes have been highlighted in reviews on the outcomes of hypoparathyroidism.
4,21
We have previously described a high prevalence of hypoparathyroidism in a population-based study at 40-47 per 100 000 7 with a particularly high rate of non-surgical hypoparathyroidism at 17 per 100 000. 7 It is thus important to note the high levels of morbidity especially in the non-surgical cases, if the prevalence of this condition is higher than previously thought. This may not be a surprise as many patients with non-surgical hypoparathyroidism will have had autoimmune causes or genetic causes with associated additional morbidities sometimes requiring additional medications such as corticosteroids.
Our results highlight the long-term morbidity associated with hypoparathyroidism which is often unrecognized by clinical staff, as well as short-term complications of managing the hypocalcaemia. 12, 16, 20 Serum calcium concentrations were directly associated with renal failure and death as was observed by Mitchell et al 16 Mean serum calcium concentration was not associated with any of the other outcomes, and neither was calcium/phosphate product (data not shown). Mean serum calcium or phosphate concentration from 6 months after diagnosis is a fairly crude measure of biochemical control, and may not reflect subtle changes in calcium concentration, which may be important in determining the outcomes assessed, and our study may be underpowered. Unfortunately, reliable data on urinary calcium excretion were not available in this population-based study. Variability in serum calcium or phosphate concentration may also be a factor in determining outcomes that we have not measured.
The mechanisms causing the adverse outcomes are not well studied. Due to a high calcium/phosphate product associated with hyperphosphataemia, it is thought that calcium phosphate crystals get deposited in the lens of the eye causing cataract, 22 and this may also contribute to arteriosclerosis precipitating cardiovascular and cerebrovascular disease, although chronic hypocalcaemia may also contribute to cardiomyopathy 23 and arrhythmias. Increased renal failure is also likely to be due to deposition of calcium phosphate.
Although hypoparathyroidism is a state of low bone turnover with increased bone density, 24 this study and previous study 9 did not show an overall increased risk of any fractures. However, an increased risk of forearm fractures has been reported. 9 It is difficult to explain the reason for increased neuropsychiatric disease, epilepsy and infection, although the ubiquitous effect of intracellular calcium stabilizing cell membranes may be relevant.
Limitations of the study include small numbers of patients (n = 280) due to the rarity of the condition, but some end-points may be under powered. In addition, we did not have data on cancer outcomes or forearm fractures, which may be at increased risk in parathyroid disease. It is possible that we may have missed some well controlled patients who had normal serum calcium throughout.
However, our prevalence rates were greater than those previously reported in the literature which is reassuring that it is unlikely that we missed large numbers of patients. We also excluded patients with low serum vitamin D concentrations to avoid being criticized for inappropriate inclusion, but this also creates a potential weakness, which may have resulted in an underestimate of the morbidity recorded. Unfortunately, we did not have detail on the causes of non-surgical hypoparathyroidism and could not distinguish between genetic, autoimmune and other causes. Additionally, we could not be sure whether the group with hypomagnesaemia had low serum magnesium due to the hypoparathyroidism or whether the hypomagnesaemia was the driving cause of the hypocalcaemia. This is the reason this group was analysed separately, as the latter group would include patients on medications, for example, diuretics and proton pump inhibitors which are markers of other confounding comorbidities such as cardiac failure. It is possible to purchase calcium and non-activated vitamin D over the counter, and we were unable to account for such prescriptions. As all prescriptions in Scotland are free, this may be less of an issue compared to some countries. A further limitation is that the date of inclusion into our study may not be the actual date of diagnosis, if diagnosis occurred some before the start of the study. Conversely, however, if there were delays in referral to a specialist, our study would identify the true date of the first low serum calcium which may be years before a specialist makes a formal diagnosis. The strength of this study includes that it is a true population-based study where patients in both primary and secondary care settings were identified. 7 Our study will include patients potentially missed using registry-based studies as discussed in detail elsewhere, 7 especially patients with milder hypocalcaemia. Patients with vitamin D deficiency were excluded, but if we have erroneously included some patients with milder hypocalcaemia, it is likely to have reduced the likelihood of any positive findings. However, the outcomes for non-surgical hypoparathyroidism were worse than those for post-surgical cases. The use of prescribing data has helped identify patients with mental illness and epilepsy.
The results from our study and others indicate that the outcomes for hypoparathyroidism are not ideal. Some complications may be related to chronic hypocalcaemia, while others may relate to relative overtreatment and chronic hypercalcaemia. All patients with persistent hypocalcaemia should get referred to a specialist clinic where they should be fully evaluated and may get better long-term care, and hopefully improved outcomes. The outcomes of death and renal failure seem to be associated with higher concentrations of serum calcium, suggesting the latter as a more significant issue for chronic complications.
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